Enzymatic DNA Synthesis Market Scope, Growth, Size and Share by 2028
Enzymatic DNA Synthesis Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 240.96 Million |
| Market Size by 2028 | US$ 2,244.88 Million |
| Global CAGR (2022 - 2028) | 45.1% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Product Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
Technology-Based Insights
Based on technology, the enzymatic DNA synthesis market is segmented into SOLA, CRISPR, PCR, and others. The PCR segment has the largest share in 2021 and is expected to continue a similar trend during the forecast period. On the other hand, the CRISPR segment is expected to witness the highest CAGR during the forecast period.
Strategies that are prominently adopted by companies in the enzymatic DNA synthesis market mergers and acquisitions. A few recent developments by key market players are listed below:
- In April 2022, GenScript launched the industry's first highest-throughput semiconductor chip for DNA synthesis at the annual Built With Biology global conference. Developed using GenScript's proprietary miniature semiconductor chip technology, this high-density DNA synthesis chip allows the synthesis of 8.4 million unique oligos simultaneously.
- In April 2022, Evonetix Ltd was granted the patent EP3551331B1 for its proprietary thermal control technology for DNA synthesis, and the design and manufacture of its silicon chips in Europe. In addition to extending Evonetix’s IP portfolio, the patent is perceived as a key step in the company’s strategy to develop a benchtop DNA synthesis platform.
- In March 2022, Molecular Assemblies, Inc. raised US$ 25.8 million Series B financing with the participation of a new investor Casdin Capital, along with all major Series A investors—Agilent Technologies, iSelect Fund, Codexis, LYFE Capital, and Argonautic Ventures. The company intends to use financing proceeds to initiate a key customer program and advance the company’s proprietary fully enzymatic DNA Synthesis technology toward early commercialization.
- In November 2021, DNA Script received a US$ 2.2 million grant from the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) to support the development of next-generation printers capable of enzymatic printing of synthetic DNA and RNA.
Company Profiles
- Telesis Bio Inc
- Evonetix
- Ansa Biotechnologies, Inc.
- Camena Bio
- GenScript Biotech Corp.
- Molecular Assemblie
- DNA Script
- Touchlight
- Synbio Technologies
- Twist Bioscience
Get Free Sample For